TY - JOUR
T1 - Analysis of air contrast barium enema, computed tomographic colonography, and colonoscopy
T2 - Prospective comparison
AU - Rockey, D. C.
AU - Paulson, E.
AU - Niedzwiecki, D.
AU - Davis, W.
AU - Bosworth, H. B.
AU - Sanders, L.
AU - Yee, J.
AU - Henderson, J.
AU - Hatten, P.
AU - Burdick, S.
AU - Sanyal, A.
AU - Rubin, D. T.
AU - Sterling, M.
AU - Akerkar, G.
AU - Bhutani, M. S.
AU - Binmoeller, K.
AU - Garvie, J.
AU - Bini, E. J.
AU - McQuaid, K.
AU - Foster, W. L.
AU - Thompson, W. M.
AU - Dachman, A.
AU - Halvorsen, R.
N1 - Funding Information:
AD is a consultant for GE Health Care and E-Z-EM, has received research funding from E-Z-EM, and is co-patent holder for CAD software licensed to R2 Technologies. All other authors declare that they have no conflict of interest.
PY - 2005/1/22
Y1 - 2005/1/22
N2 - Background The usefulness of currently available colon imaging tests, including air contrast barium enema (ACBE), computed tomographic colonography (CTC), and colonoscopy, to detect colon polyps and cancers is uncertain. We aimed to assess the sensitivity of these three imaging tests. Methods Patients with faecal occult blood, haematochezia, iron-deficiency anaemia, or a family history of colon cancer underwent three separate colon-imaging studies - ACBE, followed 7-14 days later by CTC and colonoscopy on the same day. The primary outcome was detection of colonic polyps and cancers. Outcomes were assessed by building an aggregate view of the colon, taking into account results of all three tests. Findings 614 patients completed all three imaging tests. When analysed on a per-patient basis, for lesions 10 mm or larger in size (n=63), the sensitivity of ACBE was 48% (95% CI 35-61), CTC 59% (46-71, p=0·1083 for CTC vs ACBE), and colonoscopy 98% (91-100, p<0·0001 for colonoscopy vs CTC). For lesions 6-9 mm in size (n=116), sensitivity was 35% for ACBE (27-45), 51% for CTC (41-60, p=0·0080 for CTC vs ACBE), and 99% for colonoscopy (95-100, p<0·0001 for colonoscopy vs CTC). For lesions of 10 mm or larger in size, the specificity was greater for colonoscopy (0·996) than for either ACBE (0·90) or CTC (0·96) and declined for ACBE and CTC when smaller lesions were considered. Interpretation Colonoscopy was more sensitive than other tests, as currently undertaken, for detection of colonic polyps and cancers. These data have important implications for diagnostic use of colon imaging tests.
AB - Background The usefulness of currently available colon imaging tests, including air contrast barium enema (ACBE), computed tomographic colonography (CTC), and colonoscopy, to detect colon polyps and cancers is uncertain. We aimed to assess the sensitivity of these three imaging tests. Methods Patients with faecal occult blood, haematochezia, iron-deficiency anaemia, or a family history of colon cancer underwent three separate colon-imaging studies - ACBE, followed 7-14 days later by CTC and colonoscopy on the same day. The primary outcome was detection of colonic polyps and cancers. Outcomes were assessed by building an aggregate view of the colon, taking into account results of all three tests. Findings 614 patients completed all three imaging tests. When analysed on a per-patient basis, for lesions 10 mm or larger in size (n=63), the sensitivity of ACBE was 48% (95% CI 35-61), CTC 59% (46-71, p=0·1083 for CTC vs ACBE), and colonoscopy 98% (91-100, p<0·0001 for colonoscopy vs CTC). For lesions 6-9 mm in size (n=116), sensitivity was 35% for ACBE (27-45), 51% for CTC (41-60, p=0·0080 for CTC vs ACBE), and 99% for colonoscopy (95-100, p<0·0001 for colonoscopy vs CTC). For lesions of 10 mm or larger in size, the specificity was greater for colonoscopy (0·996) than for either ACBE (0·90) or CTC (0·96) and declined for ACBE and CTC when smaller lesions were considered. Interpretation Colonoscopy was more sensitive than other tests, as currently undertaken, for detection of colonic polyps and cancers. These data have important implications for diagnostic use of colon imaging tests.
UR - http://www.scopus.com/inward/record.url?scp=19944433150&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(05)70194-X
DO - 10.1016/S0140-6736(05)70194-X
M3 - Article
C2 - 15664225
AN - SCOPUS:19944433150
SN - 0140-6736
VL - 365
SP - 305
EP - 311
JO - The Lancet
JF - The Lancet
IS - 9456
ER -